Cadila Healthcare has received a letter from the US Food and Drug Administration (USFDA) classifying the inspection conducted at the company's Moraiya facility located at Ahmedabad, Gujarat from April 22, 2019 to May 3, 2019 as 'Official Action Indicated' (OAI).
The company believes that this classification will not have any impact on the current supplies or revenues of this facility. The company is in the process of sending further updates of its corrective actions to the USFDA and remains hopeful of a positive outcome.
Cadila Healthcare operates in areas of active pharmaceutical ingredients (API) to formulations, and animal health products to cosmeceuticals.
Your portfolio may have substantial downside risks!
Review your portfolio with MoneyWorks4me and get it future ready. Let us not miss our hard earned gains. Book your Free demo to discuss with our Experts.